29 3月 2018 by admin in UncategorizedComments resTORbio Reports Fourth Quarter and Full Year 2017 Financial Results
29 3月 2018 by admin in UncategorizedComments ARMO BioSciences Enrolls First Patient in the CYPRESS 2 Trial Evaluating AM0010 in Non-Small Cell Lung Cancer
28 3月 2018 by admin in UncategorizedComments Tempest Therapeutics Closes $70 Million Series B Financing – Cancer immunology programs launched from Versant’s Inception Discovery Engine –
26 3月 2018 by admin in UncategorizedComments ARMO BioSciences Announces Positive Outcome of First Interim Analysis in SEQUOIA Phase 3 Pancreatic Cancer Study
19 3月 2018 by admin in UncategorizedComments resTORbio Announces Formation of Clinical Advisory Board
12 3月 2018 by admin in UncategorizedComments Syros Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Accomplishments and Anticipated Milestones
01 3月 2018 by admin in UncategorizedComments Centrexion Therapeutics to Present CNTX-4975 Clinical Data at the American Academy of Orthopaedic Surgeons 2018 Annual Meeting
